Table 2.
Higher anti-CXCR3 and anti-CXCR4 antibody levels are associated with stable lung function parameters
| Parameter | Patients above cut-off (%) | Patients below cut-off (%) | p values | Number of analyzed patients | Hazard ratios | ||
|---|---|---|---|---|---|---|---|
| Deterioration ≥ 10% | No deterioration | Deterioration ≥ 10% | No deterioration | ||||
| Anti-CXCR3 antibodies | |||||||
| FVC (%) | 25.0 | 75.0 | 59.3 | 40.7 | ≤ 0.01 | 59 | 0.32 |
| FEV1 (%) | 23.5 | 76.5 | 71.1 | 28.9 | ≤ 0.001 | 72 | 0.22 |
| DLCO-SB (%) | 36.4 | 63.6 | 63.6 | 36.4 | ≤ 0.05 | 55 | 0.47 |
| DLCO/VA (%) | 42.4 | 57.6 | 70.4 | 29.6 | ≤ 0.05 | 60 | 0.38 |
| Anti-CXCR4 antibodies | |||||||
| FVC (%) | 22.2 | 77.8 | 70.0 | 30.0 | ≤ 0.001 | 47 | 0.2 |
| FEV1 (%) | 33.3 | 66.7 | 78.6 | 21.4 | ≤ 0.001 | 61 | 0.27 |
| TLC (%) | 33.3 | 66.7 | 64.7 | 35.3 | ≤ 0.05 | 44 | 0.33 |
| DLCO-SB (%) | 43.3 | 56.7 | 75.0 | 25.0 | ≤ 0.05 | 46 | 0.46 |
| DLCO/VA (%) | 39.4 | 60.6 | 82.4 | 17.6 | ≤ 0.001 | 50 | 0.24 |
Patients with antibody levels above and below cut-off, with and without deterioration in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), total lung capacity (TLC), the diffusing capacity for carbon monoxide (DLCO) measured by a single breath (DLCO-SB), and DLCO/VA within 3 years, p values (log-rank test) as well as number of analyzed patients are shown
Hazard ratios derived from the Cox proportional hazards model highlight the relationship between deterioration in lung function parameters and anti-CXCR3/anti-CXCR4 antibody levels